Relative Value

There is not enough data to reliably calculate the relative value of Neximmune Inc.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
vs History
vs Industry
Median 3Y
-3.6
Median 5Y
-3.9
Industry
23.7
Forward
-113
vs History
vs Industry
Median 3Y
-4.3
Median 5Y
-4.6
Industry
22
vs History
vs Industry
Median 3Y
-4.3
Median 5Y
-4.6
Industry
24.3
vs History
vs Industry
Median 3Y
30.2
Median 5Y
30.4
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.2
vs History
vs Industry
Median 3Y
-3.5
Median 5Y
-3.7
Industry
6.1
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-3.6
Industry
6.5
Forward
-2.8
vs History
vs Industry
Median 3Y
-4.1
Median 5Y
-4.4
Industry
7.9
vs History
vs Industry
Median 3Y
-4.1
Median 5Y
-4.4
Industry
6.3
vs History
vs Industry
Median 3Y
23.7
Median 5Y
25.3
Industry
5.7

Multiples Across Competitors

Competitors Multiples
Neximmune Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Neximmune Inc
F:737
86.1m EUR 0 -3.9 -3.8 -3.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 790 068.7 -160 599.2 -195 018.6 -192 793.3
US
Abbvie Inc
NYSE:ABBV
403.8B USD 6.8 172 16.6 23.6
US
Amgen Inc
NASDAQ:AMGN
176.1B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
152.4B USD 5.2 18.8 12.6 12.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.2B USD 9.8 31.3 23 24
US
Epizyme Inc
F:EPE
94.1B EUR 2 084.9 -532 -579.3 -563.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD 5.7 17.8 16.9 19.2
AU
CSL Ltd
ASX:CSL
83.3B AUD 3.6 18.5 12.5 15.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD 16.3 1 203 162.2 196.7
NL
argenx SE
XBRU:ARGX
44.1B EUR 14.4 33.8 58.2 59.8
P/S Multiple
Revenue Growth P/S to Growth
US
Neximmune Inc
F:737
Average P/S: 3 379 222
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 790 068.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 084.9
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.3
46%
0.4
NL
argenx SE
XBRU:ARGX
14.4
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Neximmune Inc
F:737
Average P/E: 190
Negative Multiple: -3.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 599.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.8
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.3
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
10%
1.8
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 203
N/A N/A
NL
argenx SE
XBRU:ARGX
33.8
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Neximmune Inc
F:737
Average EV/EBITDA: 40
Negative Multiple: -3.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 018.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
11%
1.5
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
162.2
N/A N/A
NL
argenx SE
XBRU:ARGX
58.2
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Neximmune Inc
F:737
Average EV/EBIT: 46.2
Negative Multiple: -3.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 793.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.6
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.2
13%
1.5
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
196.7
N/A N/A
NL
argenx SE
XBRU:ARGX
59.8
N/A N/A